Effectiveness of sequential administration of G-CSF and GM-CSF after antineoplastic chemotherapy in patients with advanced tumors : results of a randomized trial
Recent in vitro data have shown that growth factors are more effective when used in combination. This synergy between cytokines, when translated in a clinical setting, should permit a reduction of dosage, and therefore of toxicity. We sought to determine whether the sequential administration of low doses of G-CSF followed by low doses of GM-CSF could be effective both in protecting from neutropenia, and in reducing side effects. A randomized single blind phase III study was carried out. Patients considered to be eligible for the study were designated to receive a minimum of 3 chemotherapy cycles for treatment of metastatic or locally advanced cancer. Patients were randomized to receive, from the 8th day to the 13th day of cycle, G-CSF, 2.5 micrograms/kg/day s.c., or G-CSF, 2.5 micrograms/kg/day s.c. for the first 3 days, followed by GM-CSF, 2.5 micrograms/kg/day s.c. for the last 3 days. The number of delays in relation to the number of cycles, the number of patients whose therapies were deferred, and the total number of days of delay in relation to the total number of days of observation were significantly different, with far fewer delays in the group treated with the G-GM sequence. Our study confirms that the sequential administration of G-CSF and GM-CSF is highly synergistic. This synergy allows clinicians to administer chemotherapy treatments to pre-treated and/or elderly patients, with minimal risk of toxicity and no need for delays or dosage reduction.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1997 |
|---|---|
| Erschienen: |
1997 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
Tumori - 83(1997), 5 Suppl vom: 29. Sept., Seite S13-6 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Efficacia della somministrazione sequenziale di G-CSF e GM-CSF dopo chemioterapia antitumorale in pazienti in fase avanzata: risultati di uno studio randomizzato |
|---|
| Beteiligte Personen: |
Mustacchi, G [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 27.01.1998 Date Revised 13.12.2017 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM093893574 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM093893574 | ||
| 003 | DE-627 | ||
| 005 | 20231222094529.0 | ||
| 007 | tu | ||
| 008 | 231222s1997 xx ||||| 00| ||ita c | ||
| 028 | 5 | 2 | |a pubmed24n0313.xml |
| 035 | |a (DE-627)NLM093893574 | ||
| 035 | |a (NLM)9446253 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Mustacchi, G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of sequential administration of G-CSF and GM-CSF after antineoplastic chemotherapy in patients with advanced tumors |b results of a randomized trial |
| 246 | 3 | 3 | |a Efficacia della somministrazione sequenziale di G-CSF e GM-CSF dopo chemioterapia antitumorale in pazienti in fase avanzata: risultati di uno studio randomizzato |
| 264 | 1 | |c 1997 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 27.01.1998 | ||
| 500 | |a Date Revised 13.12.2017 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Recent in vitro data have shown that growth factors are more effective when used in combination. This synergy between cytokines, when translated in a clinical setting, should permit a reduction of dosage, and therefore of toxicity. We sought to determine whether the sequential administration of low doses of G-CSF followed by low doses of GM-CSF could be effective both in protecting from neutropenia, and in reducing side effects. A randomized single blind phase III study was carried out. Patients considered to be eligible for the study were designated to receive a minimum of 3 chemotherapy cycles for treatment of metastatic or locally advanced cancer. Patients were randomized to receive, from the 8th day to the 13th day of cycle, G-CSF, 2.5 micrograms/kg/day s.c., or G-CSF, 2.5 micrograms/kg/day s.c. for the first 3 days, followed by GM-CSF, 2.5 micrograms/kg/day s.c. for the last 3 days. The number of delays in relation to the number of cycles, the number of patients whose therapies were deferred, and the total number of days of delay in relation to the total number of days of observation were significantly different, with far fewer delays in the group treated with the G-GM sequence. Our study confirms that the sequential administration of G-CSF and GM-CSF is highly synergistic. This synergy allows clinicians to administer chemotherapy treatments to pre-treated and/or elderly patients, with minimal risk of toxicity and no need for delays or dosage reduction | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Granulocyte Colony-Stimulating Factor |2 NLM | |
| 650 | 7 | |a 143011-72-7 |2 NLM | |
| 650 | 7 | |a Granulocyte-Macrophage Colony-Stimulating Factor |2 NLM | |
| 650 | 7 | |a 83869-56-1 |2 NLM | |
| 700 | 1 | |a Ceccherini, R |e verfasserin |4 aut | |
| 700 | 1 | |a Milani, S |e verfasserin |4 aut | |
| 700 | 1 | |a Sandri, P |e verfasserin |4 aut | |
| 700 | 1 | |a Leita, M L |e verfasserin |4 aut | |
| 700 | 1 | |a Carbonara, T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tumori |d 1946 |g 83(1997), 5 Suppl vom: 29. Sept., Seite S13-6 |w (DE-627)NLM000245321 |x 2038-2529 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:1997 |g number:5 Suppl |g day:29 |g month:09 |g pages:S13-6 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 1997 |e 5 Suppl |b 29 |c 09 |h S13-6 | ||